Skip to main content
Year archive

Vivoryon Therapeutics N.V. — 2016 filings

All 33 regulatory filings released by Vivoryon Therapeutics N.V. (VVY) in 2016, sourced directly from the official regulator.

33 Filings
2016 Period
2016 filings (33)
Filing Released Lang
Probiodrug: Innovative Phase II study design of Glutaminylcyclase Inhibitor PQ912 in early Alzheimer's disease
Regulatory Filings
2016-12-08 English
Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer's mouse model
Regulatory Filings
2016-11-16 English
Probiodrug reports Third Quarter 2016 Business Update
Interim / Quarterly Report Q3 2016
2016-11-10 English
Probiodrug AG to Publish its Third Quarter 2016 Business Update on 10 November 2016
Report Publication Announcement
2016-11-03 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-10-13 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-10-12 English
Probiodrug AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2016-10-11 English
Probiodrug AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2016-10-11 English
Probiodrug launches capital increase by means of an accelerated bookbuild offering
Capital/Financing Update
2016-10-06 English
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 & pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
Regulatory Filings
2016-09-13 English
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model
Regulatory Filings
2016-09-07 English
Probiodrug reports financial results for H1 2016
Interim / Quarterly Report H1 2016
2016-08-30 English
Probiodrug AG to Publish First Half 2016 Results on 30 August 2016
Report Publication Announcement
2016-08-23 English
Capital/Financing Update 2016
Capital/Financing Update
2016-08-23 English
Probiodrug and Crossbeta Biosciences enter into a strategic partnership in the field of Alzheimer's disease biomarkers
Regulatory Filings
2016-06-30 English
Probiodrug:Two key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of Alzheimer's disease (AD) granted in Japan
Regulatory Filings
2016-06-09 English
Probiodrug reports First Quarter 2016 Business Update
Interim / Quarterly Report Q1 2016
2016-05-12 English
Probiodrug to Present at the 1st Meeting of The Society for CSF analysis and Clinical Neurochemistry
Regulatory Filings
2016-05-11 English
Probiodrug AG to Publish its First Quarter 2016 Business Update on May 12, 2016
Report Publication Announcement
2016-05-04 English
Probiodrug to Attend and Present at European Conferences in May 2016
Regulatory Filings
2016-05-03 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-04-28 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-04-13 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-04-12 English
Probiodrug to hold its Ordinary General Meeting of Shareholders on May 19, 2016
AGM Information
2016-04-06 English
Probiodrug AG: Bekanntmachung der Einberufung zur Hauptversammlung am 19.05.2016 in Berlin mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2016-04-05 German
Probiodrug announces results of chronic toxicology studies with PQ912, its 'first in class' Glutaminyl Cyclase (QC) inhibitor for the treatment of Alzheimer's disease
Earnings Release Q2 2016
2016-04-04 English
Probiodrug Appoints Mark Booth as Chief Business Officer
Board/Management Information
2016-03-23 English
Probiodrug Reports Full Year 2015 Financial Results
Earnings Release FY 2015
2016-03-15 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements
2016-03-11 English
Probiodrug's pGlu-Abeta Approaches being presented at 14th AAT Symposium on Advances in Alzheimer Therapy
Regulatory Filings
2016-03-09 English
Probiodrug AG to Publish its Full Year 2015 Results on March 15, 2016
Report Publication Announcement
2016-03-07 English
Report Publication Announcement 2016
Report Publication Announcement
2016-03-07 English
Key patents granted for Probiodrug's pGlu-Abeta targeting monoclonal antibody program for the treatment of Alzheimer's disease
Regulatory Filings
2016-01-11 English